Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA ® (enlicitide) tablets 20 mg as an adjunct ...
GV Wire

Israel Kills Four People in Gaza, Including a Child, Medics Say

A tragic Israeli airstrike in Gaza claims a family of three, leaving a young boy as the sole survivor amid ongoing ceasefire talks.